Pfizer earnings beat by $0.14, revenue topped estimates

Pfizer reported third quarter EPS of $0.87, $0.14 higher than the analyst estimate of $0.73. The company's revenue for the quarter was $16.6 billion, surpassing the consensus estimate of $15.91 billion. Pfizer anticipates FY 2026 EPS of $2.95-$3.05, slightly above the analyst consensus of $2.96. For FY 2026, Pfizer forecasts revenue between $62.00 billion and $64.00 billion, close to the analyst consensus of $62.20 billion.

Pfizer's stock price ended at $30.67, marking a 17.06% increase over the past three months and a 26.21% rise in the last year. The company has experienced 2 upward EPS revisions and 15 downward revisions in the last 90 days. Pfizer's Financial Health score is rated as "great performance." For more information on Pfizer's recent earnings performance and financials, visit Investing.com. To stay informed on upcoming earnings reports, consult Investing.com's earnings calendar.